Frank McCormick, Chairman of Oncology at BridgeBio Pharma, Inc. (BBIO), sold 200,000 shares at $42.22 ($8.6M) on 2020-11-13, disclosed to the SEC on 2020-11-17.
Open-market sale of $8.6M BBIO by Chairman of Oncology. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $42.22 | 31,632 | $1.3M | 15.6% |
| 2 | $42.22 | 31,632 | $1.3M | 15.6% |
| 3 | $42.91 | 58,299 | $2.5M | 29.3% |
| 4 | $42.91 | 58,299 | $2.5M | 29.3% |
| 5 | $43.57 | 10,069 | $439K | 5.1% |
| 6 | $43.57 | 10,069 |
| $439K |
| 5.1% |
| Total | $42.76 avg | 200,000 | $8.6M | 100% |
| Filing → |
| BBIO | SELL | 2025-09-08 | $7.9M | — | Filing → |
| BBIO | SELL | 2025-06-26 | $4.4M | — | Filing → |
| BBIO | SELL | 2023-12-28 | $4.2M | — | Filing → |